XM
SRPT icon

XTX Markets’s Sarepta Therapeutics SRPT Stock Holding History

XTX Markets’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$205K Buy
+1,205
New +$179K 0.42% 134

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

XTX Markets's SRPT Position: Q4 2020 in Review

XTX Markets opened a new position in Sarepta Therapeutics (SRPT) in Q4 2020: 1,205 shares worth $205K. The stake represents 0.42% of the portfolio and ranks #134 among its holdings.

455 funds tracked by Wall St. Rank hold SRPT as of Q4 2020.

  • XTX Markets held 1,205 shares of Sarepta Therapeutics worth $205K as of Q4 2020.
  • Sarepta Therapeutics was a new XTX Markets position in Q4 2020.
  • Sarepta Therapeutics made up 0.42% of XTX Markets's portfolio in Q4 2020, its #134 holding.
  • 455 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.